HKG:2652

3 stories mentioning HKG:2652Updated 36d ago

Every FINWIRES story that references HKG:2652, newest first.

CF PharmTech Clears GMP Inspection for Suzhou Inhalation Drug Facility

CF PharmTech (HKG:2652) said its inhalation formulation production base in Suzhou passed a good manufacturing practice inspection conducted by the drug regulator of a member country of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme, according to a Thursday Hong Kong bourse filing.The inspection covered the facility's production management and quality control systems, premises, equipment, data integrity, and computerized systems.Shares of the pharmaceutical firm were up over 1% in Friday morning trade.

HKG:2652

Asia44d ago

CF PharmTech Files Southeast Asia Marketing Authorization Application for Inhalation Drug; Shares Up 4%

CF PharmTech (HKG:2652) submitted a marketing authorization application for CF017, a budesonide suspension for inhalation, in a Southeast Asian market, according to a Thursday Hong Kong bourse filing.The drug was approved in China in 2021 and has since been commercialized in the mainland, the filing said.Shares of the company rose nearly 4% in morning trade Thursday.

HKG:2652

Asia46d ago

CF PharmTech's Bronchospasm Secures China Marketing Approval

CF PharmTech (HKG:2652) said Chinese regulators had accepted its marketing authorization application for tiotropium bromide inhalation powder for review, according to a Tuesday filing with the Hong Kong bourse.The product is designed to treat bronchospasm associated with chronic obstructive pulmonary disease and help keep reduce exacerbations associated with the condition.

HKG:2652

Track with the FINWIRES app suite

FolioX

Track HKG:2652 in your portfolio

WheelAI

Analyze HKG:2652 options with the wheel strategy

StockInsider

See market sentiment on HKG:2652